Edgar Filing: Edge Therapeutics, Inc. - Form 4

Edge Therapeuti Form 4 October 08, 201										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION							OMB APPROVAL			
Washington, D.C. 20549Washington, D.C. 20549Check this box if no longer subject to Section 16.STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESForm 4 or Form 5 obligations 					Number: Expires: Estimated a burden hou response n	irs per				
(Print or Type Responses)										
MARCHIO ALBERT N II Symbol			2. Issuer Name and Ticker or Trading mbol dge Therapeutics, Inc. [EDGE]				5. Relationship of Reporting Person(s) to Issuer			
(Last) 200 CONNELL 1600	(First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year) 10/06/2015			L	(Check all applicable) <u> </u>				
			endment, Date Original onth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
1.Title of 2.	Transaction Date 2A. Do Aonth/Day/Year) Execution Any	eemed ion Date, if	Code (D) Year) (Instr. 8) (Instr. 3, 4 and 5) (A)		cquired d of	• • •	Amount of 6. Ownership ecurities Form: Direct eneficially (D) or wned Indirect (I) ollowing (Instr. 4) eported ransaction(s)			
Common 10	0/06/2015		Code V C		or (D)	Price	(Instr. 3 and 4)	D		
Stock	0/06/2015		C	5,504	A	<u>(1)</u>	5,504	D		
Common 10 Stock	0/06/2015		Р	100	А	\$ 11	6,504	D		
Common 10 Stock	0/06/2015		J <u>(2)</u>	357	А	\$ 7.24	6,861	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: Edge Therapeutics, Inc. - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration E (Month/Day	Date	7. Title and A Underlying S (Instr. 3 and	Securities	8. l De Seo (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Series C-1 Convertible Preferred Stock	<u>(1)</u>	10/06/2015		С	7,530	<u>(1)</u>	<u>(1)</u>	Common Stock	5,504	

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
MARCHIO ALBERT N II 200 CONNELL DRIVE, SUITE 1600 BERKELEY HEIGHTS, NJ 07922			Chief Acct. & Op., Asst. Sec.			

Signatures

/s/ Albert N. Marchio II	10/08/2015		
**Signature of Reporting	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The convertible preferred stock converted into the Issuer's common stock at a conversion ratio, as adjusted to give effect to the Issuer's
 (1) 1-for-1.3681 reverse stock split effected on September 21, 2015, of one share of common stock for every 1.3681 shares of preferred stock immediately prior to the closing of the Issuer's initial public offering of common stock, and had no expiration date.
- (2) The Reporting Person received a total of 357 shares of the Issuer's common stock which represented a payment-in-kind dividend on 7,530 shares of the Issuer's convertible preferred stock owned at the time of the dividend payment date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.